Clearside Biomedical Announces Multiple Presentations on Suprachoroidal Delivery to be Featured at the 25th EURETINA Congress
Clearside Biomedical (Nasdaq: CLSD) announced multiple presentations featuring its SCS Microinjector庐 platform at the upcoming 25th EURETINA Congress in Paris from September 4-7, 2025. The presentations will highlight the company's suprachoroidal delivery platform designed for treating various retinal diseases including wet AMD, diabetic retinopathy, and geographic atrophy.
Key presentations include Phase 2b results from the ODYSSEY trial and Phase 3 program updates for CLS-AX in neovascular age-related macular degeneration, presented by Dr. Sobha Sivaprasad. Dr. Victor Chong, Chief Medical Officer, will present a decade-long review of suprachoroidal drug delivery evolution and participate in a panel discussion on geographic atrophy at the Ophthalmology Futures Retina Forum.
Clearside Biomedical (Nasdaq: CLSD) ha annunciato diverse presentazioni che illustreranno la sua piattaforma SCS Microinjector庐 al 25潞 Congresso EURETINA che si terr脿 a Parigi dal 4 al 7 settembre 2025. Le sessioni metteranno in luce la tecnologia di somministrazione suprachoroidale sviluppata per il trattamento di diverse patologie retiniche, tra cui AMD umida, retinopatia diabetica e atrofia geografica.
Tra gli interventi principali figurano i risultati di fase 2b dallo studio ODYSSEY e gli aggiornamenti sul programma di fase 3 per CLS-AX nella degenerazione maculare neovascolare, presentati dalla Dr.ssa Sobha Sivaprasad. Il Dr. Victor Chong, Chief Medical Officer, presenter脿 una rassegna decennale sull鈥檈voluzione della somministrazione suprachoroidale dei farmaci e parteciper脿 a una tavola rotonda sull鈥檃trofia geografica durante l鈥橭phthalmology Futures Retina Forum.
Clearside Biomedical (Nasdaq: CLSD) anunci贸 m煤ltiples presentaciones que mostrar谩n su plataforma SCS Microinjector庐 en el 25.潞 Congreso de EURETINA en Par铆s, del 4 al 7 de septiembre de 2025. Las presentaciones destacar谩n la plataforma de administraci贸n suprachoroidea dise帽ada para tratar diversas enfermedades de la retina, incluyendo AMD exudativa, retinopat铆a diab茅tica y atrofia geogr谩fica.
Entre las presentaciones clave est谩n los resultados de fase 2b del ensayo ODYSSEY y las actualizaciones del programa de fase 3 para CLS-AX en degeneraci贸n macular neovascular, que presentar谩 la Dra. Sobha Sivaprasad. El Dr. Victor Chong, Director M茅dico, ofrecer谩 una revisi贸n de la evoluci贸n de la administraci贸n suprachoroidea en la 煤ltima d茅cada y participar谩 en un panel sobre atrofia geogr谩fica en el Ophthalmology Futures Retina Forum.
Clearside Biomedical (雮橃姢雼�: CLSD)電� 2025雲� 9鞗� 4鞚茧秬韯� 7鞚缄箤歆� 韺岆Μ鞐愳劀 鞐措Μ電� 鞝�25須� EURETINA 頃欗殞鞐愳劀 鞛愳偓鞚� SCS Microinjector庐 頂岆灚韽� 甏�霠� 鞐煬 氚滍憸毳� 歆勴枆頃滊嫟瓿� 氚滍憸頄堨姷雼堧嫟. 氚滍憸鞐愳劀電� 鞀奠劚 AMD, 雼闺嚚氤戩劚 毵濍氤戩, 歆�毽爜 鞙勳稌 霌� 雼れ枒頃� 毵濍 歆堩櫂 旃橂毳� 鞙勴暣 靹り硠霅� 齑堧毵�(鞀堩攧霛检綌搿滌澊雼�) 鞎诫 鞝勲嫭 頂岆灚韽检潉 靻岅皽頃╇媹雼�.
欤检殧 氚滍憸搿滊姅 ODYSSEY 鞁滍棙鞚� 2b靸� 瓴瓣臣鞕� 鞁犾儩順堦磤靹� 鞐半牴甏�霠櫓氚橂硛靹� 旃橂鞝� CLS-AX鞚� 3靸� 頂勲攴鸽灗 鞐呺嵃鞚错姼臧� 鞛堨溂氅�, 鞚措姅 靻岆皵 鞁滊皵頂勲澕靷摐 氚曥偓臧� 氚滍憸頃╇媹雼�. 牍呿劙 齑�(Victor Chong) 鞚橅暀毂呾瀯鞛愲姅 齑堧毵� 鞎诫 鞝勲嫭鞚� 10雲勱皠 氚滌爠靷ゼ 氚滍憸頃橁碃 Ophthalmology Futures Retina Forum鞐愳劀 歆�毽爜 鞙勳稌 甏�霠� 韺剱 韱犾潣鞐� 彀胳棳頃� 鞓堨爼鞛呺媹雼�.
Clearside Biomedical (Nasdaq: CLSD) a annonc茅 plusieurs pr茅sentations mettant en avant sa plateforme SCS Microinjector庐 lors du 25e congr猫s EURETINA 脿 Paris, du 4 au 7 septembre 2025. Les interventions mettront en lumi猫re la plateforme d鈥檃dministration suprachoro茂dienne destin茅e au traitement de diverses maladies de la r茅tine, y compris la DMLA exsudative, la r茅tinopathie diab茅tique et l鈥檃trophie g茅ographique.
Parmi les pr茅sentations cl茅s figurent les r茅sultats de phase 2b de l鈥檈ssai ODYSSEY et les mises 脿 jour du programme de phase 3 pour CLS-AX dans la d茅g茅n茅rescence maculaire n茅ovasculaire, pr茅sent茅s par la Dre Sobha Sivaprasad. Le Dr Victor Chong, Chief Medical Officer, pr茅sentera une revue de dix ans de l鈥櫭﹙olution de l鈥檃dministration suprachoro茂dienne et participera 脿 une table ronde sur l鈥檃trophie g茅ographique lors de l鈥橭phthalmology Futures Retina Forum.
Clearside Biomedical (Nasdaq: CLSD) gab mehrere Pr盲sentationen zu seiner SCS Microinjector庐-Plattform auf dem 25. EURETINA-Kongress in Paris vom 4. bis 7. September 2025 bekannt. Die Beitr盲ge werden die suprachoroidale Applikationsplattform des Unternehmens hervorheben, die zur Behandlung verschiedener Netzhauterkrankungen wie feuchter AMD, diabetischer Retinopathie und geografischer Atrophie entwickelt wurde.
Zu den Schwerpunkten z盲hlen die Phase-2b-Ergebnisse der ODYSSEY-Studie sowie Updates zum Phase-3-Programm f眉r CLS-AX bei neovaskul盲rer altersbedingter Makuladegeneration, pr盲sentiert von Dr. Sobha Sivaprasad. Dr. Victor Chong, Chief Medical Officer, wird einen zehnj盲hrigen 脺berblick 眉ber die Entwicklung der suprachoroidalen Wirkstoffapplikation geben und an einer Paneldiskussion zur geografischen Atrophie im Ophthalmology Futures Retina Forum teilnehmen.
- None.
- None.
Insights
Clearside's upcoming presentations on suprachoroidal delivery platform and CLS-AX program represent important clinical progress for their retinal disease pipeline.
Clearside Biomedical is advancing its innovative suprachoroidal delivery platform with multiple presentations scheduled at the upcoming EURETINA Congress. The company's SCS Microinjector庐 technology enables targeted drug delivery to the back of the eye, potentially addressing multiple retinal diseases including wet AMD, diabetic retinopathy, diabetic macular edema, geographic atrophy and ocular cancer.
Most significantly, the company will present Phase 2b results from the ODYSSEY trial for CLS-AX (axitinib injectable suspension) in neovascular age-related macular degeneration alongside details about their Phase 3 program design, which has received FDA alignment. This progression to late-stage development indicates the company is advancing its lead candidate through the regulatory pathway.
Clearside is also expanding its pipeline with a new streamlined Phase 2 trial in non-proliferative diabetic retinopathy, demonstrating pipeline diversification beyond their initial wet AMD focus. The company's partnership with REGENXBIO for suprachoroidal gene therapy delivery (ALTITUDE study) further validates their platform technology.
The presentations' focus on geographic atrophy is particularly noteworthy, as this represents a significant unmet medical need with growing market potential as the population ages. The company believes their approach may improve efficacy for small molecules and complement inhibition while potentially reducing systemic and anterior segment side effects - addressing key challenges in current treatment options.
These developments collectively showcase Clearside's progress in leveraging their proprietary delivery platform across multiple high-value retinal indications, potentially expanding their addressable market and clinical relevance.
- Presentations Highlight the Versatility of Clearside鈥檚 SCS Microinjector庐 Platform for the Treatment of Multiple Retinal Diseases -
- CLS-AX Trial Designs in Wet AMD and Diabetic Retinopathy to be Featured in Presentation by Dr. Sobha Sivaprasad -
ALPHARETTA, Ga., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc.聽(Nasdaq: CLSD) (鈥淐learside鈥� or the 鈥淐ompany鈥�), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS庐), announced today that its SCS delivery platform and CLS-AX program will be highlighted in multiple presentations at the 25th EURETINA Congress from September 4 - 7, 2025 in Paris, France. Victor Chong, MD, MBA, Chief Medical Officer and EVP, Head of Research and Development will also participate in a panel discussion at the preceding Ophthalmology Futures Retina Forum on September 3, 2025.
Clearside鈥檚 suprachoroidal delivery platform is designed to enable targeted treatment for multiple retinal diseases, including wet AMD, diabetic retinopathy, diabetic macular edema, geographic atrophy and ocular cancer.
鈥淲e are excited to showcase our SCS Microinjector庐 platform and advancements with our CLS-AX program at these prominent medical meetings in Europe,鈥� said Dr. Chong. 鈥淔or CLS-AX, we have designed a Phase 3 trial in wet AMD in alignment with the U.S. FDA, and a new, streamlined Phase 2 trial design in non-proliferative diabetic retinopathy. In addition, we believe suprachoroidal delivery has the potential to provide a targeted approach for the treatment of geographic atrophy, enabling drug dispersion directly to the choroid and retina while potentially minimizing systemic and anterior segment side effects. This method may offer improved efficacy for small molecules and complement inhibition in both the retinal pigment epithelium and choroid,鈥� Dr. Chong concluded.
25th EURETINA Congress
Title: Suprachoroidally Administered CLS-AX in Participants with Neovascular Age-Related Macular Degeneration: Phase 2b Results from ODYSSEY and Phase 3 Program Update
Presenter: Sobha Sivaprasad, MD, Professor of Retinal Clinical Research, Consultant Ophthalmologist, Moorfields Eye Hospital, London, UK
Date: Saturday, September 6, 2025, 16:06 - 16:12 CEST
Title: A Decade-Long Review of the Evolution of Suprachoroidal Drug Delivery with a Focus on Axitinib Injectable Suspension for Neovascular Age-Related Macular Degeneration
Presenter: Victor Chong, MD, MBA, Chief Medical Officer and EVP, Head of Research and Development
Date: Saturday, September 6, 2025, 14:27 - 14:33 CEST
Partner: REGENXBIO
Title: Suprachoroidal gene therapy for diabetic retinopathy (ALTITUDE study)
Presenter: Lejla Vajzovic, MD, Associate Professor of Ophthalmology at Duke University School of Medicine
Date: Thursday, September 4, 2025, 11:13 - 11:20 CEST
Ophthalmology Futures Retina Forum
Title: Geographic Atrophy & Intermediate AMD: Lessons Learned from Glaucoma & Other Chronic Disease
Panelist: Victor Chong, MD, MBA, Chief Medical Officer and EVP, Head of Research and Development
Date: Wednesday, September 3, 2025, 18:40 - 19:10 CEST
About CLS-AX (axitinib injectable suspension)
CLS-AX (axitinib injectable suspension) is a proprietary suspension of axitinib for suprachoroidal injection. Axitinib is a tyrosine kinase inhibitor (TKI), currently approved as an oral tablet formulation to treat advanced renal cell carcinoma, that achieves pan-VEGF blockade, directly inhibiting VEGF receptors-1, -2, and -3 with high potency and specificity. Clearside believes this broad VEGF blockade may have efficacy advantages over existing retinal therapies by acting at a different level of the angiogenesis cascade and may benefit patients who sub-optimally respond to current, more narrowly focused anti-VEGF therapies. Suprachoroidal injection of this proprietary suspension of axitinib has demonstrated meaningful potential in Phase 1/2a and Phase 2b wet AMD clinical trials in which CLS-AX was well tolerated and demonstrated a positive safety profile. With suprachoroidal administration of axitinib, there is the potential to achieve prolonged duration and targeted delivery to affected tissue layers by compartmentalizing axitinib behind the retina, thereby limiting drug exposure to the front of the eye.
About Clearside鈥檚 Suprachoroidal Space (SCS庐) Injection Platform and SCS Microinjector庐
Clearside鈥檚 patent protected, proprietary suprachoroidal space (SCS庐) injection treatment approach offers unprecedented access to the back of the eye, where sight-threatening disease often occurs. The Company鈥檚 unique platform is inherently flexible and intended to work with established and new formulations of medications. Clearside鈥檚 patented SCS Microinjector庐 can deliver a wide variety of drug candidates into the suprachoroidal space, providing targeted delivery to potentially improve efficacy and compartmentalization of medication to reduce or eliminate toxic effects on non-diseased cells. The SCS Microinjector is comprised of a syringe with a custom-designed hub and two 30-gauge hollow microneedles of varying lengths, each approximately one millimeter, optimizing insertion and suprachoroidal administration of drugs.
About Clearside Biomedical, Inc.
Clearside Biomedical, Inc. is a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS庐) to improve patient outcomes. Clearside鈥檚 SCS injection platform, utilizing the Company鈥檚 patented SCS Microinjector庐, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina, or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases. Clearside has a pipeline of small molecule product candidates for administration via its SCS Microinjector. The Company鈥檚 lead program, , is a Phase 3 ready asset for the treatment of neovascular age-related macular degeneration (wet AMD). Clearside developed and gained approval for its first product, for suprachoroidal use, which is available in the U.S. through a commercial partner. Clearside also strategically partners its SCS injection platform with companies utilizing other ophthalmic therapeutic innovations. For more information, please visit or follow us on and .
Cautionary Note Regarding Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as 鈥渂elieve鈥�, 鈥渆xpect鈥�, 鈥渕ay鈥�, 鈥減lan鈥�, 鈥減otential鈥�, 鈥渨ill鈥�, and similar expressions, and are based on Clearside鈥檚 current beliefs and expectations. These forward-looking statements include statements regarding the clinical development of Clearside鈥檚 product candidates, and the potential benefits of CLS-AX, Clearside鈥檚 suprachoroidal delivery technology and Clearside鈥檚 SCS Microinjector庐. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include uncertainties inherent in the conduct of clinical trials, Clearside鈥檚 reliance on third parties over which it may not always have full control, Clearside's ability to raise additional capital, and other risks and uncertainties that are described in Clearside鈥檚 Annual Report on Form 10-K for the year ended December 31, 2024, filed with the U.S. Securities and Exchange Commission (SEC) on March 27, 2025, Clearside鈥檚 Quarterly Report on Form 10-Q filed with the SEC on August 8, 2025 and Clearside鈥檚 other periodic reports filed with the SEC. Any forward-looking statements speak only as of the date of this press release and are based on information available to Clearside as of the date of this release, and Clearside assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.
Source: Clearside Biomedical, Inc.
Investor and Media Contact: [email protected]
FAQ
What will Clearside Biomedical (CLSD) present at EURETINA Congress 2025?
What retinal diseases can Clearside's suprachoroidal delivery platform potentially treat?
When and where will CLSD's presentations take place at EURETINA 2025?
What are the potential advantages of Clearside's suprachoroidal delivery method?
Who are the key presenters for Clearside at EURETINA 2025?
